9th Annual Biomarkers Congress
New Frontiers in Cancer Drug Development
World Trade Center Boston
200 Seaport Boulevard
Boston, MA 02210
New Frontiers in Cancer Drug Development
Drug Discovery

Schedule of Presentations:

Wednesday, August 5, 2009
07:30:00 Registration and Coffee
08:30:00 Conference Chair Opening Remarks Lyuba Varticovski
08:35:00 Understanding and Exploiting the Role of Cancer Stem Cells in Drug Development
08:40:00 Targeting Cancer Stem Cells Timothy Hoey
09:15:00 Selection and Expansion of Stem-like Cells from Solid Tumors Based on Growth and Survival Properties: Cell Surface Antigens Useful as Drug Targets Jenny P. Mather
09:50:00 Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update Ivan Bergstein
10:20:00 Networking Refreshment Break in Poster & Exhibit Hall
11:00:00 Targeting the Hedgehog Pathway in Cancer Treatment Chia Portera
11:05:00 Strategic Discussion Group
11:30:00 Cancer Stem Cells Chia Portera, Ivan Bergstein, Jenny P. Mather, Timothy Hoey, Lyuba Varticovski
11:30:00 Conference Keynote
12:00:00 George D. Demetri, M.D. From Empiric to Specific: How Can We Translate Science into Cancer Treatments and Get it Right More Reliably?
12:30:00 Networking Luncheon in Exhibit & Poster Hall
13:00:00 New Approaches for Targeting Cancer
13:45:00 The Lin28 Oncogene and Pluripotency Factor is a Potential Target in Cancer Stem Cells Hao Zhu
14:10:00 A New Paradigm for Translational Cancer Research: Targeting Endocrine Factors and Real Human Tumors Sandra S. McAllister
14:35:00 AMG 386, an Anti-Angiogenic Agent Targeting the Angiopoietin-Tie2 Pathway Jon Oliner
15:00:00 Targeting Chromatin Modifying Enzymes as an Epigenetic Therapy for Cancer Patrick Trojer
15:05:00 Technology Workshop
15:25:00 MDS Pharma Services Genotype-correlated Phenotypic Drug Discovery- OncoPanelâ„¢ Usha Warrior
15:50:00 Networking Refreshment Break in Exhibit & Poster Hall
15:55:00 POINT/COUNTERPOINT: Innovation Starvation in Oncology Drug Development: Implications for R&D Strategies
16:00:00 POINT: The industry is changing and the current approach to first-in-class innovation in oncology isn't working.
16:30:00 Is There Evidence that First-in-class Innovation in Oncology is Dwindling? John Herrmann
16:35:00 COUNTERPOINT: Novel target discovery platforms are feeding innovation in oncology
16:55:00 FunctionFIRST: A Novel Antibody/Target Discovery Platform Daniel S. Pereira
17:20:00 Discussion
17:45:00 Close of Day One
18:00:00 Attendee Networking Dinner
Thursday, August 6, 2009
08:30:00 Conference Chair Opening Remarks Helen Chen
08:35:00 Combination Cancer Therapies and Multi-Targeting Strategies for Novel Therapeutics
08:35:00 Combination of Molecularly Targeted Agents: Opportunities and Challenges Helen Chen
08:40:00 Featured Presentation
09:05:00 The Evolving Treatment Paradigm in Multiple Myeloma Kenneth C Anderson
09:35:00 A Novel Approach to Combination Therapy through Cancer Network Disruption: Curis' Multi-Targeted Inhibitor Platform Daniel Passeri
10:05:00 Interplay Between EGFR-TKI Resistance Mechanisms, EMT Biology and a Rationale for Multi-Targeting David M. Epstein
10:35:00 Networking Refreshment Break
11:05:00 The Use of Genetically Engineered Mouse Lung Cancer Models to Assess Effectiveness of Targeted Therapeutic Combinations Kwok-Kin Wong
11:35:00 Strategic Discussion Group
11:35:00 Bevacizumab in Patients with Previously Treated Glioblastoma Asha Das
12:05:00 Are Targeted Therapies Better than Non-Targeted Therapies?
12:45:00 Networking Luncheon with Attendee/Speaker Chat Sessions
12:50:00 Extrapolating Preclinical Models to the Clinic Kevin P. Foley, Murray O. Robinson
13:00:00 Strategies to Exploit Epigenetic Mechanisms for Drug Discovery Patrick Trojer
13:15:00 Functional Definition of a Companion Diagnostic: Strategies for Fit-for-Purpose Development John C Bloom
13:30:00 Combinations of Novel and Conventional Cancer Agents: Challenges and Opportunities Helen Chen, Kenneth C Anderson
13:40:00 Translational Medicine: Predictive and Pharmacodynamic Biomarkers in Cancer Drug Development Nicholas C. Dracopoli
13:50:00 Biomarker Clinical Utility: How Can Qualification of a Biomarker's Clinical Utility Be Determined? Prospective or Retrospective or a Combination? Scott D Patterson
13:55:00 Increasing Success in Oncology Drug Development
14:00:00 Turning Cancer Sequencing Data into Therapeutic Targets Heidi Greulich
14:30:00 Effective Use of Animal Models during Preclinical Development of a Vascular Disrupting Agent Kevin P. Foley
15:00:00 Networking Refreshment Break
15:30:00 Targeting the JAK/STAT Pathway in Solid Tumors with the JAK2 Inhibitor AZD1480
16:00:00 The Pharmacology Audit Trail: Connecting Discovery Research and Clinical Science in Oncology Drug Development Chris H. Takimoto
16:15:00 Strategic Discussion Group
16:30:00 Increasing Success in Oncology Drug Development Vojo Vukovic
17:00:00 Close of Conference
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.